Cargando…

Natalizumab Rebound in Multiple Sclerosis

Detalles Bibliográficos
Autores principales:	Lee, Joshua D., Chen, Tychicus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Images in Clinical Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689555/ https://www.ncbi.nlm.nih.gov/pubmed/34950414 http://dx.doi.org/10.1177/19418744211031360

Ejemplares similares

Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis
por: Kim, Ki Hoon, et al.
Publicado: (2021)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
por: Guger, Michael, et al.
Publicado: (2020)

Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal
por: Koska, Valeria, et al.
Publicado: (2021)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
por: Boziki, Marina, et al.
Publicado: (2021)

Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy
por: Gattringer, Thomas, et al.
Publicado: (2014)

Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis
por: Frisch, Esther S., et al.
Publicado: (2023)

The Successful Treatment of Severe Trigeminal Neuralgia by a Single Mandibular Nerve Block and Subsequent Natalizumab Administration in a Patient with Multiple Sclerosis
por: Norioka, Ryohei, et al.
Publicado: (2020)

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
por: Butzkueven, Helmut, et al.
Publicado: (2020)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation
por: González‐Suarez, Inés, et al.
Publicado: (2017)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy
por: Giacoppo, Sabrina, et al.
Publicado: (2017)

Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab
por: Mancuso, Roberta, et al.
Publicado: (2022)

Rebound effect following intravitreal bevacizumab in branch retinal vein occlusion
por: Deka, Satyen, et al.
Publicado: (2009)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021)

Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report
por: Patti, Francesco, et al.
Publicado: (2015)

Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
por: Capuano, Rocco, et al.
Publicado: (2021)

Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab
por: Sood, Arjun B., et al.
Publicado: (2016)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
por: Steinman, Lawrence
Publicado: (2012)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

Cognitive evolution in natalizumab-treated multiple sclerosis patients
por: Jacques, Francois H, et al.
Publicado: (2016)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary
por: Dobson, Ruth, et al.
Publicado: (2022)

Influence of natalizumab on resting-state connectivity in patients with multiple sclerosis
por: Corrêa, Diogo G., et al.
Publicado: (2023)

Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis
por: Milstein, Joshua L., et al.
Publicado: (2019)

Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound
por: Janoschka, Claudia, et al.
Publicado: (2022)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
por: Ganapathy Subramanian, Ranjani, et al.
Publicado: (2021)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab
por: Patti, Francesco, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_et8m3madaueqgo2vhpkdpjqmdi